Billing Challenges Unique to Labs & Diagnostic Centers
A lab or diagnostic center billing team can do everything right by the standards that govern physician office billing and still get lab billing wrong, because labs run on a fundamentally different regulatory framework. PAMA fee schedules, Local Coverage Determinations, CLIA compliance, and ABN issuance rules don't have close equivalents in a typical physician practice's billing process — which means the usual playbook doesn't fully transfer.
PAMA changed how lab reimbursement gets set — and reported
The Protecting Access to Medicare Act (PAMA) requires applicable laboratories to report private payer rates and volumes for clinical diagnostic laboratory tests, which CMS then uses to set the Medicare Clinical Laboratory Fee Schedule. Getting this reporting wrong, or missing reporting obligations entirely, has downstream consequences for reimbursement rates that a lab may not connect back to a compliance filing made months earlier. It's a reporting requirement with no real analog in physician billing, and it's easy for a lab that grew out of a hospital or physician-office billing background to underweight it.
LCD compliance requires systematic diagnosis matching, not manual review
Medicare's Local Coverage Determinations define which diagnoses justify which tests, and coverage varies by Medicare Administrative Contractor jurisdiction. Manually verifying LCD compliance against every requisition is realistic at low volume; it stops being realistic well before a lab reaches meaningful scale. Without a systematic diagnosis-matching process, non-covered tests get billed as if covered, and denials follow — often in a pattern that's invisible until someone reconciles a batch of claims against the actual LCD criteria that applied at the time of service.
ABN workflows have to trigger correctly, not become a blanket habit
Advance Beneficiary Notices exist to shift financial responsibility to the patient when a test isn't expected to be covered — but they only work as intended when issued before testing, tied to an actual expectation of non-coverage under the applicable LCD. Labs under volume pressure sometimes drift toward issuing ABNs broadly as a hedge, which creates its own compliance exposure: a blanket ABN practice can be read as an attempt to shift liability rather than a genuine coverage determination, and that's a pattern regulators know to look for.
Molecular and toxicology testing draws disproportionate scrutiny
High-volume molecular diagnostic and toxicology billing has drawn sustained federal program-integrity attention for years, reflected in repeated OIG work plan items and payer-side utilization review targeting these test categories specifically. That scrutiny isn't a reflection of any particular lab's practices — it's a category-wide pattern that means documentation and coding discipline for molecular and toxicology panels needs to hold up under audit as a matter of course, not just when a specific claim gets flagged.
The common thread
Each of these — PAMA reporting, LCD compliance, ABN discipline, and audit-ready molecular/toxicology documentation — is a distinct regulatory obligation with its own failure mode. A lab that's excellent at PAMA reporting can still have a live LCD compliance gap, and vice versa. Treating lab billing as "physician billing but for tests" is usually where the gap starts. See how we approach laboratory and diagnostics billing for labs and diagnostic centers navigating this regulatory framework at any test volume.